![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1494905
D-¾Æ¹Ì³ë»ê ½ÃÀå ¿¹Ãø(-2030³â) : À¯Çüº°, Á¦Á¶ ¹æ¹ýº°, Çüź°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¼¼°è ºÐ¼®D-Amino Acid Market Forecasts to 2030 - Global Analysis By Type, Production Method, Form, Application, End User and By Geography |
Stratistics MRC¿¡ µû¸£¸é ¼¼°è D-¾Æ¹Ì³ë»ê ½ÃÀåÀº 2024³â 1¾ï 8,690¸¸ ´Þ·¯·Î ¿¹Ãø ±â°£ µ¿¾È CAGR 5.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 2¾ï 5,470¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
D-¾Æ¹Ì³ë»ê(D-¾Æ¹Ì³ë»ê)Àº ÀÚ¿¬ÀûÀ¸·Î Á¸ÀçÇÏ´Â L-¾Æ¹Ì³ë»êÀÇ °Å¿ï»ó ÇüÅÂÀ̸ç, ºÐÀÚ ±¸Á¶ÀÇ D-±¸¼ºÀ¸·Î ±¸º°µÇ¸ç, L-¾Æ¹Ì³ë»êÀÌ ÁÖ·Î ´Ü¹éÁú¿¡ Æ÷ÇԵǴ ¹Ý¸é, D-¾Æ¹Ì³ë»êÀº ´Ù¾çÇÑ »ý¹°ÇÐÀû °úÁ¤¿¡¼ °íÀ¯ÇÑ ¿ªÇÒÀ» Çϸç, ÀǾàǰ, ½Äǰ ÷°¡¹° ¹× »ê¾÷ ÀÀ¿ë ºÐ¾ß¿¡ »ç¿ëµË´Ï´Ù. D-¾Æ¹Ì³ë»êÀº ¾à¹°ÀÇ ¾ÈÁ¤¼º°ú Ȱ¼º¿¡ ¶Ñ·ÇÇÑ ÀÌÁ¡À» Á¦°øÇÏ¿© »ý¸í°øÇÐ ¹× ÀÇÇÐ ºÐ¾ß¿¡¼ Àü¹®ÀûÀÎ »ç¿ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
À¯·´Á¦¾àÇùȸ(EFPIA)¿¡ µû¸£¸é 2020³â À¯·´ ÀǾàǰ ÃÑ »ý»ê·®Àº 3,100¾ï À¯·Î(¾à 3,540¾ï 8,076¸¸ ´Þ·¯)·Î 2019³â ´ëºñ 5.7% Áõ°¡Çß½À´Ï´Ù.
½Äǰ ¹× »ç·á ÷°¡Á¦ »ç¿ë Áõ°¡
½Äǰ ¹× »ç·á ÷°¡¹°¿¡¼ D-¾Æ¹Ì³ë»ê ¼ö¿ä Áõ°¡´Â ½ÃÀåÀÇ Áß¿äÇÑ ÃËÁøÁ¦À̸ç, D-¾Æ¹Ì³ë»êÀº dz¹Ì Áõ°Á¦, ¿µ¾ç º¸ÃæÁ¦ ¹× »ç·á ÷°¡Á¦·Î »ç¿ëµÇ¾î µ¿¹°ÀÇ °Ç°°ú ¼ºÀåÀ» Çâ»ó½Ãŵ´Ï´Ù. ÀÚ¿¬½º·´°í °Ç°ÇÑ ½Äǰ¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼ µ¿¹°¼º Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ÇÔ²² ÀÌ·¯ÇÑ ÀÀ¿ë ºÐ¾ß¿¡¼ D-¾Æ¹Ì³ë»ê »ç¿ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
³ôÀº »ý»ê ºñ¿ë
D-¾Æ¹Ì³ë»ê°ú °ü·ÃµÈ ³ôÀº Á¦Á¶ ºñ¿ëÀº ½ÃÀåÀÇ ÁÖ¿ä ¾ïÁ¦¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Á¦Á¶ °øÁ¤¿¡´Â º¹ÀâÇÑ È¿¼Ò ¹ÝÀÀ°ú Á¤Á¦ ´Ü°è°¡ Æ÷ÇԵǸç, ÀÌ´Â ºñ¿ë »ó½ÂÀÇ ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦ÇÑµÈ ¿ø·áÀÇ °¡¿ë¼º, Ư¼ö Àåºñ¿Í ¼÷·ÃµÈ ³ëµ¿·ÂÀÇ Çʿ伺Àº Á¦Á¶ ºñ¿ëÀ» ´õ¿í Áõ°¡½Ãŵ´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº ºñ¿ëÀº °¡°Ý¿¡ ¹Î°¨ÇÑ ÀÀ¿ë ºÐ¾ß¿Í ½ÃÀå¿¡¼ D-¾Æ¹Ì³ë»ê äÅÃÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.
»ý¸í°øÇÐÀÇ ¹ßÀü
À¯Àü°øÇÐ, È¿¼Ò ±â¼ú ¹× ¹ßÈ¿ °øÁ¤ÀÇ ¹ßÀüÀ¸·Î D-¾Æ¹Ì³ë»ê »ý»êÀÌ º¸´Ù È¿À²ÀûÀÌ°í ºñ¿ë È¿À²ÀûÀÎ »ý»êÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ ¹ßÀüÀº ¹Ì»ý¹° ±ÕÁÖÀÇ ÃÖÀûÈ, ¼öÀ² ¹× ¼øµµ Çâ»ó, ´ëü ¿ø·áÀÇ Å½»öÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. »ý¸í°øÇÐÀÇ Çõ½ÅÀº »ý»ê ¹®Á¦¸¦ ±Øº¹Çϰí D-¾Æ¹Ì³ë»ê Àû¿ë ¹üÀ§¸¦ È®´ëÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
ÇÕ¼º ´ëüǰ°úÀÇ °æÀï
D-¾Æ¹Ì³ë»ê ½ÃÀåÀº ÇÕ¼º ´ëüǰÀÇ À§Çù¿¡ Á÷¸éÇØ ÀÖÀ¸¸ç, D-¾Æ¹Ì³ë»êÀÇ Æ¯¼º°ú ±â´ÉÀ» ¸ð¹æÇÑ ÇÕ¼º ÈÇÕ¹°ÀÌ °æÀï·Â ÀÖ´Â ´ëüǰÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÇÕ¼º ´ëü ÈÇÕ¹°Àº »ý»ê ºñ¿ë Àý°¨, ¾ÈÁ¤ÀûÀΠǰÁú, ¼Õ½¬¿î È®À强 µîÀÇ ÀÌÁ¡À» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇÕ¼º ´ëüǰÀÇ °¡¿ë¼º ¹× äÅà Áõ°¡´Â õ¿¬ D-¾Æ¹Ì³ë»ê ¼ö¿ä¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ½ÃÀå ¼ºÀå¿¡ À§ÇùÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
COVID-19´Â D-¾Æ¹Ì³ë»ê ½ÃÀå¿¡ ´Ù¾çÇÑ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ½Äǰ ¹× »ç·á »ê¾÷ÀÇ D-¾Æ¹Ì³ë»ê ¼ö¿ä´Â °ø±Þ¸Á ¹®Á¦¿Í ¼ÒºñÀÚ ÁöÃâ °¨¼Ò·Î ÀÎÇØ È¥¶õÀ» °Þ¾úÁö¸¸, D-¾Æ¹Ì³ë»ê ÇÔÀ¯ °Ç° º¸Á¶ ½ÄǰÀ» Æ÷ÇÔÇÑ °Ç° ¹× À£ºù Á¦Ç°¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁ³½À´Ï´Ù. ±×·¯³ª COVID-19·Î ÀÎÇÑ °æ±â µÐÈ¿Í Á¦Á¶ ¹× ¹«¿ª Ȱµ¿ÀÇ Á¦ÇÑÀº ÀÌ ±â°£ µ¿¾È ½ÃÀå ¼ºÀå¿¡ ¾î·Á¿òÀ» °Þ¾ú½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È D-¾Ë¶ó´Ñ ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
D-¾Ë¶ó´Ñ ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È D-¾Æ¹Ì³ë»ê ½ÃÀå¿¡¼ °¡Àå Å« ºÐ¾ß°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. D-¾Ë¶ó´ÑÀº ½Äǰ »ê¾÷¿¡¼ dz¹Ì ÁõÁøÁ¦, µ¿¹° ¿µ¾ç °³¼±À» À§ÇÑ »ç·á ÷°¡Á¦, Á¦¾à »ê¾÷¿¡¼ ÆéŸÀ̵å ÇÕ¼ºÀ» À§ÇÑ ºôµù ºí·ÏÀ¸·Î ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, D-¾Ë¶ó´ÑÀº ÀÌ·¯ÇÑ ÁÖ¿ä ÀÀ¿ë ºÐ¾ß¿¡¼ ´ÙÀç´Ù´ÉÇÏ°í ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå¿¡¼ ¾ÐµµÀû ÀÎ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.¿¡¼ ´ÙÀç´Ù´ÉÇÏ°í ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó D-¾Ë¶ó´ÑÀº ½ÃÀå¿¡¼ ¾ÐµµÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
¿µ¾ç º¸ÃæÁ¦ ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿µ¾ç º¸ÃæÁ¦ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È D-¾Æ¹Ì³ë»ê ½ÃÀå¿¡¼ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °Ç° ¹× À£ºù¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ »ýȰ½À°üº´ À¯º´·ü Áõ°¡¿Í ÇÔ²² °Ç°±â´É½Äǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, D-¾Æ¹Ì³ë»êÀº ÀÎÁö ±â´É °³¼± ¹× ±ÙÀ° ȸº¹°ú °°Àº ÀáÀçÀûÀÎ °Ç° È¿°ú·Î ÀÎÇØ °Ç°±â´É½Äǰ¿¡ Á¡Á¡ ´õ ¸¹ÀÌ Ã·°¡µÇ°í ÀÖ½À´Ï´Ù. °Ç°º¸Á¶½Äǰ »ê¾÷ÀÇ ³ôÀº ¼ºÀå ÀáÀç·Â°ú D-¾Æ¹Ì³ë»ê »ç¿ë È®´ë´Â ÀÌ ºÐ¾ßÀÇ ±Þ°ÝÇÑ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹Ì°¡ D-¾Æ¹Ì³ë»ê ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀÇ ¿ìÀ§´Â źźÇÑ ½Äǰ ¹× Á¦¾à »ê¾÷ÀÇ Á¸Àç, °Ç°°ú ¿µ¾ç¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ³ôÀº ÀνÄ, ¿ìÈ£ÀûÀÎ ±ÔÁ¦ ȯ°æ µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº ±â´É¼º ½Äǰ, °Ç°º¸Á¶½Äǰ, ÷´Ü ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä¿¡ ÈûÀÔ¾î D-¾Æ¹Ì³ë»êÀÇ ÁÖ¿ä ½ÃÀåÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ °·ÂÇÑ R&D ¿ª·®°ú »ý¸í°øÇÐ ±â¼ú ¹ßÀüµµ D-¾Æ¹Ì³ë»ê ½ÃÀå¿¡¼ÀÇ ¼±µµÀû ÁöÀ§¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È D-¾Æ¹Ì³ë»ê ½ÃÀå¿¡¼ °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀÇ ¼ºÀåÀº °¡Ã³ºÐ ¼Òµæ Áõ°¡, ½Ä½À°ü ¼±È£µµ º¯È, ¼ÒºñÀÚÀÇ °Ç° ÀÎ½Ä Áõ°¡ µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. Áß±¹, ÀϺ», Àεµ¿Í °°Àº ±¹°¡µéÀº Àα¸ Áõ°¡, ½Äǰ ¹× »ç·á »ê¾÷ È®Àå, ¿µ¾ç º¸ÃæÁ¦ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í ÷´Ü »ý¸í°øÇÐ ±â¼úÀÇ Ã¤ÅÃÀº ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ D-¾Æ¹Ì³ë»ê ½ÃÀåÀÇ ±Þ°ÝÇÑ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
According to Stratistics MRC, the Global D-Amino Acid Market is accounted for $186.9 million in 2024 and is expected to reach $254.7 million by 2030 growing at a CAGR of 5.2% during the forecast period. D-amino acids are the mirror-image forms of naturally occurring L-amino acids, distinguished by their D-configuration in the molecular structure. While L-amino acids are predominantly found in proteins, D-amino acids have unique roles in various biological processes and are utilized in pharmaceuticals, food additives, and industrial applications. They offer distinct advantages in drug stability and activity, contributing to their specialized use in biotechnology and medicine.
According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2020, the total production of pharmaceuticals in Europe was EURO 310,000 million (approximately US$354,080.76 million), an increase of 5.7% over 2019
Increasing use in food and feed additives
The growing demand for D-amino acids in food and feed additives is a significant driver for the market. D-amino acids are used as flavor enhancers, nutritional supplements, and feed additives to improve animal health and growth. The increasing consumer preference for natural and healthy food products, coupled with the rising demand for animal-based products, is fueling the use of D-amino acids in these applications, thereby driving market growth.
High production costs
The high production costs associated with D-amino acids are a major restraint for the market. The manufacturing process involves complex enzymatic reactions and purification steps, which contribute to the elevated costs. Additionally, the limited availability of raw materials and the need for specialized equipment and skilled labor further increase production expenses. These high costs can limit the adoption of D-amino acids in price-sensitive applications and markets.
Advancements in biotechnology
Developments in genetic engineering, enzyme technology, and fermentation processes are enabling more efficient and cost-effective production of D-amino acids. These technological advancements allow for the optimization of microbial strains, improvement of yield and purity, and the exploration of alternative raw materials. Biotechnology innovations can help overcome production challenges and expand the application scope of D-amino acids.
Competition from synthetic alternatives
The D-amino acid market faces a threat from synthetic alternatives. Synthetic compounds that mimic the properties and functions of D-amino acids are emerging as competitive substitutes. These synthetic alternatives may offer advantages such as lower production costs, consistent quality, and easier scalability. The increasing availability and adoption of synthetic alternatives can potentially impact the demand for natural D-amino acids and pose a threat to market growth.
The Covid-19 pandemic has had a mixed impact on the D-amino acid market. While the demand for D-amino acids in the food and feed industries experienced some disruptions due to supply chain challenges and reduced consumer spending, the market also witnessed increased interest in health and wellness products, including nutritional supplements containing D-amino acids. However, the pandemic-induced economic slowdown and restrictions on manufacturing and trade activities posed challenges for market growth during this period.
The D-Alanine segment is expected to be the largest during the forecast period
The D-Alanine segment is projected to be the largest segment in the D-amino acid market during the forecast period. This can be attributed to its wide range of applications in various industries. D-Alanine is extensively used as a flavor enhancer in the food industry, as a feed additive to improve animal nutrition, and as a building block for peptide synthesis in the pharmaceutical industry. The versatility and increasing demand for D-Alanine across these key application areas contribute to its dominant market position.
The nutritional supplements segment is expected to have the highest CAGR during the forecast period
The nutritional supplements segment is anticipated to exhibit the highest CAGR in the D-amino acid market during the forecast period. The growing consumer awareness about health and wellness, coupled with the rising prevalence of lifestyle-related diseases, is driving the demand for nutritional supplements. D-amino acids are increasingly being incorporated into dietary supplements due to their potential health benefits, such as improved cognitive function and muscle recovery. The high growth potential of the nutritional supplements industry and the expanding application of D-amino acids in this segment are expected to fuel its rapid growth.
North America is expected to hold the largest share in the D-amino acid market. The region's dominance can be attributed to several factors, including the presence of well-established food and pharmaceutical industries, high consumer awareness about health and nutrition, and supportive regulatory environment. The United States, in particular, is a major market for D-amino acids, driven by the demand for functional foods, dietary supplements, and advanced pharmaceutical formulations. The region's strong research and development capabilities and technological advancements in biotechnology also contribute to its leading position in the D-amino acid market.
The Asia Pacific region is projected to witness the highest CAGR in the D-amino acid market during the forecast period. The region's growth can be attributed to factors such as rising disposable incomes, changing dietary preferences, and increasing health consciousness among consumers. Countries like China, Japan, and India are major contributors to the market's growth, driven by their large populations, expanding food and feed industries, and growing demand for nutritional supplements. The region's increasing investments in research and development, coupled with the adoption of advanced biotechnology techniques, are expected to further fuel the rapid growth of the D-amino acid market in Asia Pacific.
Key players in the market
Some of the key players in D-Amino Acid Market include Ajinomoto Co., Inc., Evonik Industries AG, Sigma-Aldrich (Merck KGaA), Kyowa Hakko Bio Co., Ltd., Thermo Fisher Scientific Inc., Central Drug House (P) Ltd., Amino GmbH, TCI Chemicals (India) Pvt. Ltd., Tokyo Chemical Industry Co., Ltd., PepTech Corporation, Wuhan Amino Acid Bio-Chemical Co., Ltd., Chemical Dynamics Corporation, AnaSpec, Inc., LifeSpan BioSciences, Inc., CBL Biotech Pvt. Ltd., Enzo Life Sciences, Inc., Bio-Synthesis Inc., Zhejiang NHU Company Ltd., Santa Cruz Biotechnology, Inc., and Creative Peptides.
In April 2024, Merck, a leading science and technology company, has launched the first all-in-one, validated genetic stability assay of its kind. The Aptegra(TM) CHO genetic stability assay leverages whole genome sequencing and bioinformatics to significantly accelerate biosafety testing for clients and therefore, their move into commercial production.
In January 2024, Qatar Free Zones Authority (QFZ) and Evonik, a leading specialty Chemicals Company headquartered in Germany, have signed a Memorandum of Understanding (MoU) at the sidelines of the Qatar Economic Forum. The common aim is to explore specific investment opportunities focused on sustainable solutions for energy transition.
In December 2023, Ajinomoto Co., Inc. announced that it completed procedures on December 21, 2023 (local time) for acquisition of all equities of Forge Biologics Holdings, LLC ("Forge") through its consolidated subsidiary Ajinomoto North America Holdings, Inc., in line with its press release "Ajinomoto Group Acquires Forge Biologics, a US-Based Gene Therapy CDMO for Approximately JPY 82.8 Billion".